Johnson & Johnson (J&J) Develops the Third COVID-19 Vaccine to be Considered by U.S. Regulatory Authorities
The J&J vaccine division, Janssen Pharmaceuticals, reports that their vaccine is 66% protective against moderate to severe COVID-19 infection in a multi-country study.